# Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

> **NCT01624285** · PHASE2 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Adult Primary Hepatocellular Carcinoma
- Localized Resectable Adult Primary Liver Cancer
- Localized Unresectable Adult Primary Liver Cancer
- Recurrent Adult Primary Liver Cancer

## Interventions

- **DRUG:** sorafenib tosylate
- **OTHER:** placebo
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01624285
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07-16
- **Primary completion:** 2023-02
- **Final completion:** 2023-02
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624285, "Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01624285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*